As Chief Financial Officer and Treasurer, Mr. Clifton is responsible for the company’s financial, operating, strategy and business development activites.
Mr. Clifton brings to Zevra significant public company and global operations leadership experience, along with expertise in managed care contracting, compliance, investor relations, and business development.
Prior to joining Zevra in 2015, Mr. Clifton served as Chief Financial Officer, Secretary and Treasurer of The LGL Group, Inc., a publicly held global producer of highly engineered electronic components and services.
Mr. Clifton also previously served as Chief Financial Officer of a21, Inc., a publicly held holding company with businesses in stock photography and the online retail and manufacture of framed art, as well as a variety of finance, medical cost analysis, and managed care provider contracting roles with Aetna, Inc.
Mr. Clifton was an auditor with KPMG, LLP, and received his B.B.A. and M.B.A. from the University of North Florida. Mr. Clifton is a Certified Public Accountant in the State of Florida.
How old is R. LaDuane Clifton?
Mr. Clifton is currently 52 years old. There are 4 older executives and no younger executives at Zevra Therapeutics. The oldest executive at Zevra Therapeutics is Mr. Rahsaan W. Thompson J.D., Chief Legal Officer, Secretary & Compliance Officer, who is 53 years old. Learn More on R. LaDuane Clifton's age.
How do I contact R. LaDuane Clifton?
Has R. LaDuane Clifton been buying or selling shares of Zevra Therapeutics?
Who are Zevra Therapeutics' active insiders?
Are insiders buying or selling shares of Zevra Therapeutics?
In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 5 times. They sold a total of 105,273 shares worth more than $885,165.78. The most recent insider tranaction occured on October, 10th when CEO Neil F Mcfarlane sold 19,500 shares worth more than $210,990.00. Insiders at Zevra Therapeutics own 2.4% of the company.
Learn More about insider trades at Zevra Therapeutics. Information on this page was last updated on 10/10/2025.
